| Name | gly-met-ala-ser-lys-ala-gly-ala-ile-ala-gly-lys-ile-ala-lys-val-ala-leu-lys-ala-leu-nh2 |
|---|---|
| Synonyms | PGLa |
| Description | PGLa is an antimicrobial peptide. PGLa is known to be bacteriostatic against both Gram-positive and Gram-negative bacteria. |
|---|---|
| Related Catalog | |
| Target |
Anti-bacteria[1] |
| In Vitro | PGLa is known to be bacteriostatic against both Gram-positive and Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, Streptococcus pyogenes, and Staphylococcus aureus), without much selectivity between the two types of bacterial cells. PGLa is synthesized as a native (the wild type) peptide and as a mutant with a norleucine instead of methionine at position 2Met (designated PGLa(Nle)). |
| References |
| Molecular Formula | C88H162N26O22S |
|---|---|
| Molecular Weight | 1968.45000 |
| Exact Mass | 1967.21000 |
| PSA | 800.72000 |
| LogP | 4.65010 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |